Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia

Cancer Cell

Volumn 30, Issue 6, 2016, Pages 849-862

  Ebinger, Sarah ^a   Özdemir, Erbey Ziya ^a   Ziegenhain, Christoph ^b   Tiedt, Sebastian ^a   Castro Alves, Catarina ^a   Grunert, Michaela ^a   Dworzak, Michael ^c   Lutz, Christoph ^d   Turati, Virginia A ^e   Enver, Tariq ^e   Horny, Hans Peter ^b   Sotlar, Karl ^b   Parekh, Swati ^b   Spiekermann, Karsten ^f,g   Hiddemann, Wolfgang ^f,g   Schepers, Aloys ^a   Polzer, Bernhard ^h   Kirsch, Stefan ^h   Hoffmann, Martin ^h   Knapp, Bettina ^a   Hasenauer, Jan ^a,i   Pfeifer, Heike ^j   Panzer Grümayer, Renate ^c   Enard, Wolfgang ^b   Gires, Olivier ^f   Jeremias, Irmela ^a,f,g   more..

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g German Cancer Consortium (DKTK)   (Germany)

^h FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j GOETHE UNIVERSITY   (Germany)

more..

Author keywords

acute lymphoblastic leukemia; Cancer stem cells; dormant tumor cells; minimal residual disease (MRD); patient derived xenograft (PDX) cells; primary patients' ALL MRD cells; RNA single cell sequencing; treatment resistance

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER PATIENT; CONTROLLED STUDY; DORMANCY; GENE EXPRESSION PROFILING; GENETIC ENGINEERING; HUMAN; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ADULT; ANIMAL; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CHILD; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; PROGNOSIS; SEQUENCE ANALYSIS; SINGLE CELL ANALYSIS; TUMOR CELL CULTURE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENT; MYC PROTEIN; MYC PROTEIN, MOUSE;

ADULT; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CHILD; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEOPLASM, RESIDUAL; NEOPLASTIC STEM CELLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; SEQUENCE ANALYSIS, RNA; SINGLE-CELL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 85004073453     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.11.002     Document Type: Article

References (42)

1. Bacher, U., Kohlmann, A., Haferlach, T., Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies. Cancer Treat Rev. 36 (2010), 637–646.
2. Blatter, S., Rottenberg, S., Minimal residual disease in cancer therapy – small things make all the difference. Drug Resist Updat 21-22 (2015), 1–10.
3. Bonnet, D., Dick, J.E., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3 (1997), 730–737.
4. Castro Alves, C., Terziyska, N., Grunert, M., Gündisch, S., Graubner, U., Quintanilla-Martinez, L., Jeremias, I., Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. Blood 119 (2012), 4224–4227.
5. Clevers, H., The cancer stem cell: premises, promises and challenges. Nat. Med. 17 (2011), 313–319.
6. Eppert, K., Takenaka, K., Lechman, E.R., Waldron, L., Nilsson, B., van Galen, P., Metzeler, K.H., Poeppl, A., Ling, V., Beyene, J., et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17 (2011), 1086–1093.
7. Essers, M.A.G., Trumpp, A., Targeting leukemic stem cells by breaking their dormancy. Mol. Oncol. 4 (2010), 443–450.
8. Essers, M.A., Offner, S., Blanco-Bose, W.E., Waibler, Z., Kalinke, U., Duchosal, M.A., Trumpp, A., IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458 (2009), 904–908.
9. Fehse, B., Uhde, A., Fehse, N., Eckert, H.G., Clausen, J., Ruger, R., Koch, S., Ostertag, W., Zander, A.R., Stockschlader, M., Selective immunoaffinity-based enrichment of CD34+ cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (deltaLNGFR) gene. Hum. Gene Ther. 8 (1997), 1815–1824.
10. Gao, H., Korn, J.M., Ferretti, S., Monahan, J.E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21 (2015), 1318–1325.
11. Georgantas, R.W. 3rd, Tanadve, V., Malehorn, M., Heimfeld, S., Chen, C., Carr, L., Martinez-Murillo, F., Riggins, G., Kowalski, J., Civin, C.I., Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res. 64 (2004), 4434–4441.
12. Gokbuget, N., Stanze, D., Beck, J., Diedrich, H., Horst, H.A., Huttmann, A., Kobbe, G., Kreuzer, K.A., Leimer, L., Reichle, A., et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120 (2012), 2032–2041.
13. Graham, S.M., Vass, J.K., Holyoake, T.L., Graham, G.J., Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 25 (2007), 3111–3120.
14. Hong, D., Gupta, R., Ancliff, P., Atzberger, A., Brown, J., Soneji, S., Green, J., Colman, S., Piacibello, W., Buckle, V., et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319 (2008), 336–339.
15. Inaba, H., Greaves, M., Mullighan, C.G., Acute lymphoblastic leukaemia. Lancet 381 (2013), 1943–1955.
16. Kamel-Reid, S., Letarte, M., Sirard, C., Doedens, M., Grunberger, T., Fulop, G., Freedman, M., Phillips, R., Dick, J., A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science 246 (1989), 1597–1600.
17. Kang, H., Chen, I.M., Wilson, C.S., Bedrick, E.J., Harvey, R.C., Atlas, S.R., Devidas, M., Mullighan, C.G., Wang, X., Murphy, M., et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 115 (2010), 1394–1405.
18. Kong, Y., Yoshida, S., Saito, Y., Doi, T., Nagatoshi, Y., Fukata, M., Saito, N., Yang, S.M., Iwamoto, C., Okamura, J., et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 22 (2008), 1207–1213.
19. Kreso, A., Dick, J.E., Evolution of the cancer stem cell model. Cell Stem Cell 14 (2014), 275–291.
20. Kreso, A., O'Brien, C.A., van Galen, P., Gan, O.I., Notta, F., Brown, A.M., Ng, K., Ma, J., Wienholds, E., Dunant, C., et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339 (2013), 543–548.
21. Kunz, J.B., Rausch, T., Bandapalli, O.R., Eilers, J., Pechanska, P., Schuessele, S., Assenov, Y., Stutz, A.M., Kirschner-Schwabe, R., Hof, J., et al. Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. Haematologica 100 (2015), 1442–1450.
22. le Viseur, C., Hotfilder, M., Bomken, S., Wilson, K., Röttgers, S., Schrauder, A., Rosemann, A., Irving, J., Stam, R.W., Shultz, L.D., et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 14 (2008), 47–58.
23. Liberzon, A., Birger, C., Thorvaldsdottir, H., Ghandi, M., Mesirov, J.P., Tamayo, P., The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst 1 (2015), 417–425.
24. Lutz, C., Woll, P.S., Hall, G., Castor, A., Dreau, H., Cazzaniga, G., Zuna, J., Jensen, C., Clark, S.A., Biondi, A., et al. Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia. Leukemia 27 (2013), 1204–1207.
25. Morrison, S.J., Spradling, A.C., Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 132 (2008), 598–611.
26. Raaijmakers, M.H., Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system. Haematologica 96 (2011), 1041–1048.
27. Ravandi, F., Jorgensen, J.L., O'Brien, S.M., Jabbour, E., Thomas, D.A., Borthakur, G., Garris, R., Huang, X., Garcia-Manero, G., Burger, J.A., et al. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br. J. Haematol. 172 (2016), 392–400.
28. Rehe, K., Wilson, K., Bomken, S., Williamson, D., Irving, J., den Boer, M.L., Stanulla, M., Schrappe, M., Hall, A.G., et al. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Mol. Med. 5 (2013), 38–51.
29. Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y., et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci. Transl Med., 2, 2010, 17ra19.
30. Schillert, A., Trumpp, A., Sprick, M.R., Label retaining cells in cancer – the dormant root of evil?. Cancer Lett. 341 (2013), 73–79.
31. Schmitz, M., Breithaupt, P., Scheidegger, N., Cario, G., Bonapace, L., Meissner, B., Mirkowska, P., Tchinda, J., Niggli, F.K., Stanulla, M., et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood 118 (2011), 1854–1864.
32. Schrappe, M., Detection and management of minimal residual disease in acute lymphoblastic leukemia. Hematology 2014 (2014), 244–249.
33. Schrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W.D., Henze, G., Gadner, H., Odenwald, E., Riehm, H., Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 14 (2000), 2205–2222.
34. Takizawa, H., Regoes, R.R., Boddupalli, C.S., Bonhoeffer, S., Manz, M.G., Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation. J. Exp. Med. 208 (2011), 273–284.
35. Terziyska, N., Alves, C.C., Groiss, V., Schneider, K., Farkasova, K., Ogris, M., Wagner, E., Ehrhardt, H., Brentjens, R.J., zur Stadt, U., et al. In vivo imaging enables high resolution preclinical trials on patients’ leukemia cells growing in mice. PLoS One, 7, 2012, e52798.
36. Tesfai, Y., Ford, J., Carter, K.W., Firth, M.J., O'Leary, R.A., Gottardo, N.G., Cole, C., Kees, U.R., Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy. Leuk. Res. 36 (2012), 299–306.
37. Townsend, E.C., Murakami, M.A., Christodoulou, A., Christie, A.L., Koster, J., DeSouza, T.A., Morgan, E.A., Kallgren, S.P., Liu, H., Wu, S.C., et al. The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell 29 (2016), 574–586.
38. Trumpp, A., Essers, M., Wilson, A., Awakening dormant haematopoietic stem cells. Nat. Rev. Immunol. 10 (2010), 201–209.
39. Vick, B., Rothenberg, M., Sandhofer, N., Carlet, M., Finkenzeller, C., Krupka, C., Grunert, M., Trumpp, A., Corbacioglu, S., Ebinger, M., et al. An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging. PLoS One, 10, 2015, e0120925.
40. Visvader, J.E., Lindeman, G.J., Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8 (2008), 755–768.
41. Wilding, J.L., Bodmer, W.F., Cancer cell lines for drug discovery and development. Cancer Res. 74 (2014), 2377–2384.
42. Zhou, B.-B.S., Zhang, H., Damelin, M., Geles, K.G., Grindley, J.C., Dirks, P.B., Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8 (2009), 806–823.